Back to Global NewsPublished: 28 Feb 2026Download AppJoin TelegramAardvark's 53% Crash: Why the PWS Trial Pause May Redefine Biotech Risk#Aardvark Therapeutics#Prader-Willi Syndrome#Biotech Stocks#Clinical Trials#Healthcare InvestingDownload AppJoin CommunityShare Article